COM C. Rozwell
|
|
- Harvey Booth
- 5 years ago
- Views:
Transcription
1 C. Rozwell Research Note 6 October 2003 Commentary Technologies That Ease Pharmaceutical Industry Disruption Several disruptive forces are altering the life science business model. Enterprises must select their technology investments carefully to respond to the challenge without wasting money. The current business model of the life science industry discover a treatment for a prevalent medical condition and convince doctors to prescribe it to as many patients as possible is under severe threat from four significant forces (see Figure 1). Figure 1 Top Industry Trends Affecting Life Science Firms' Financial Performance Gartner 2003 Gartner, Inc. and/or its Affiliates. All Rights Reserved. Reproduction of this publication in any form without prior written permission is forbidden. The information contained herein has been obtained from sources believed to be reliable. Gartner disclaims all warranties as to the accuracy, completeness or adequacy of such information. Gartner shall have no liability for errors, omissions or inadequacies in the information contained herein or for interpretations thereof. The reader assumes sole responsibility for the selection of these materials to achieve its intended results. The opinions expressed herein are subject to change without notice.
2 Real-time business Connections via the Internet, wireless Location independence Disruptive forces Government intervention Price controls Regulatory scrutiny Intellectual property rights Impact Discovery shortened cycle more data and drug targets Development targeted treatments pharmacogenomics new economic model Commercialization more product launches marketing to smaller groups of consumers Manufacturing capacity shortages biopharming Scientific advances Genomics Proteomics Informatics Disruptive forces Consumer demographics Aging baby boomers Engaged and aware Globalization Source: Gartner Research (September 2003) Not the least of these disruptive forces is the science itself, which offers a two-edged sword. The mapping of the human genome augurs the potential to develop treatments that are specifically targeted to an individual's genetic profile; however, at the same time, researchers seeking to unlock the commercial potential of the new knowledge have created an exponential increase in data that needs to be captured, stored, managed and mined. As one example, in 1982, the GenBank the genetic sequence database of the National Institutes of Health held approximately half a million base pairs in its database. In 2002, it had 22 billion. Leading-edge life science firms are shifting their data management strategies from gathering and storing data to techniques that provision data on an as-needed basis to researchers for predictive drug discovery and development. A second factor stressing the industry is the change in consumer demographics. This shows up as an increase in an aging population and a trend of increasing consumerism in general. In the United States, which accounts for nearly half of the world's drug sales, the percentage of the population that is over 65 will increase 31 percent between 2001 and The 55- to 65-years old age group will increase by 63 percent. In contrast, the U.S. population as a whole will increase 13 percent, according to data from the U.S. Census Bureau. As people age, their drug consumption increases as they deal with a series of agerelated maladies such as heart disease, diabetes and cancer. This aging population has an increased need for treatments and they take multiple medications for long periods of time. The industry has yet to deal with the need for "lifetime" clinical trials to study the interaction of medications that are taken for extended intervals. The third factor is the threat of governmental intervention, which manifests itself as increasing regulatory scrutiny and pressure on industry pricing models. Gartner has noted several actions aimed at reining in the high cost of prescription medication. The latest was on 25 July 2003, when the U.S. House of 6 October
3 Representatives passed a bill to allow U.S. citizens to procure drugs abroad. Under the measure, the U.S. Department of Health and Human Services will allow importation of Food and Drug Administration (FDA)-approved drugs from Canada, the European Union and seven other nations, as long as the manufacturers use counterfeit-resistant technologies and register their production operations with the FDA. This feeds our concern that the pressure to prove the outcomes of costly treatments will increase, along with the potential that the government will launch an investigation into drug-pricing tactics. The fourth factor the emergence of the real-time enterprise is not unique to the life science industry. However, it does play out as some significant shifts in customer attitudes and behavior in the life science value web. Today's "time-tortured" customers demand speed and convenience. They expect businesses to operate around the clock. They expect suppliers to take note of their individual preferences and present customized offers to them. Consumers and business buyers expect quality, service and low cost. These are not characteristics normally associated with drug manufacturers, or the healthcare system in general. Top Technologies That Life Science Companies Need to Employ to Achieve Business Growth The impact of these four forces is rippling through the life science value network. Enterprises are pressured to shorten the discovery cycle and to kill off unpromising projects more quickly. As targeted treatments are brought to market, they will force life science companies to abandon their mass marketing strategies in favor of more-personalized marketing approaches. Instead of focusing on the physician as the focal point of sales details, they will need to learn how to reach out to smaller groups of consumers and provide them with the specific information they need to make outcomes-based decisions on treatment options. Targeted treatments also augur more manufacturing complexity. Biologics manufacturing does not scale like chemical manufacturing, so life science companies will need to find alternative sources of production capacity. This will increase the demand for contract manufacturing services. Because these four disruptive forces are hitting at the same time, they are having a compound effect on the industry. This is being manifested as a decrease in revenue, research productivity as evidenced by the reduced number of new chemical entities being approved by the FDA, despite increased spending for R&D and sales effectiveness. These pressures are spurring technology investments in areas essential to profitable operation (see "Hype Cycle for Life Sciences Technologies, 2003"). Key technologies for life science enterprises are those that support: Collaboration in the discovery process so that compounds can be evaluated quickly, and the mostpromising can be selected from among the many potential candidates. Some examples of these technologies are knowledge management, content and document management, intellectual capital management, visualization and simulation tools. Clinical trials automation tools to increase the accuracy of data collection and simplify the process of preparing regulatory submissions. Some examples are electronic data capture tools and electronic patient diaries. Sales effectiveness tools so that representatives target the most-appropriate physicians and make the best use of face-to-face details. Some examples are sales force automation tools, business intelligence, customer analytics and mobile devices. Supply chain efficiency that provides all players in the life science value network with visibility into requirements. Some examples are manufacturing execution systems, 21 CFR part 11 solutions, bar codes and electronic product codes. 6 October
4 Best Practices From the Life Science Industry Although life science companies are generally science-savvy but IT immature, there are some examples where the industry demonstrates best practices and is ahead of other industries in its use of technology to support business goals. Best Practice: Organized approach to compliance management. Because the life science industry is so highly regulated, firms take compliance seriously. They regard compliance as an ongoing activity, assign resources and allocate funds to ensure that federal regulations are being met see "Survey Shows Life Sciences Firms Complying With 21 CFR Part 11" ( and "How Life Sciences Firms Approach CFR Part 11: Survey Results" ( Next Frontier: Compliance program management office. Leading-edge life science firms are consolidating their compliance resources and establishing a corporate-level responsibility for all compliance efforts regardless of the regulatory agency headed by a chief compliance officer. They bring together disparate resources working on various aspects of compliance, such as for 21 CFR Part 11 or the U.S. Health Insurance Portability and Accountability Act, into a compliance program management office. By coordinating compliance activities into a program management office, life science firms reduce their risk exposure and resource redundancy while increasing the success of their compliance efforts. Best Practice: Data visualization. Life science firms rely on a variety of visualization and analytical tools to help them unlock the secrets in their data. Researchers explore many sources of information, internal (such as compound libraries) and external (for example, chemical content repositories or gene expression information), as they do their experiments. Scientists use visualization tools to integrate the varied sources, and present information in an interactive format so that they can explore relationships within the complex data sets. Visualization techniques enable researchers to examine large data sets perhaps with as many as 500,000 to 1 million points and quickly discern a trend. Faster analysis leads to faster speed to market. Better analysis allows researchers to pursue the most-promising opportunities and ignore those with less potential for being developed into marketable products. Next Frontier: Accelerating innovation. Life science firms are only beginning to grapple with the coordinated use of technology to accelerate drug discovery innovation. No single tool will streamline the drug discovery process, rather a series of tools and techniques will be required for researchers to tap into a variety of information sources that currently do not have any common structure. Some firms are standardizing on the same data analysis tools and have established consistent work practices with a functional area, but few have extended data and workflow integration discipline across the company. Most efforts are focused on intracompany workgroups; applying technology to multiorganization research collaboration is still in its infancy. Using technology to enable information provisioning to the desktop improves collaboration among research teams and allows firms to convert data into knowledge for drug discovery. Leading-edge life science companies are beginning to move away from data warehouses constructed as passive accumulations of information, and are facilitating the timely access to, and distribution of, data sources to enable real-time decision making. They are also making research information available outside of the discovery organization to clinical, marketing and manufacturing groups. Bottom Line: Four disruptive forces are rendering many life science business practices less effective, or even obsolete. As enterprises struggle to bolster anemic research pipelines, they still need to adhere to strict government regulations that ensure product quality and patient safety. Life science companies generally lag other industries in their use of IT to support business processes; however, recent pressure 6 October
5 on profit has forced them to take a new look at technologies that support the collaboration necessary for faster speed to market. Meanwhile, the industry provides some best practices in its compliance management programs and the use of visualization tools for drug discovery. 6 October
1Q04 Update: Silicon Demand Will Move to a Full Recovery
Gartner Dataquest Alert 1Q04 Update: Silicon Demand Will Move to a Full Recovery Our latest silicon demand forecast indicates that wafer demand in 2003 will increase 9 percent over 2002. While the forecast
More informationSilicon Wafer Demand Forecast Update, 4Q03
Forecast Analysis Silicon Wafer Demand Forecast Update, 4Q03 Abstract: Silicon wafer demand in 2003 will register an 8 percent increase over 2002. Demand will enter an expansion phase in the second quarter
More informationSilicon Wafer Demand Outlook: Forecast Update, 2Q03
Research Brief Silicon Wafer Demand Outlook: Forecast Update, 2Q03 Abstract: The latest silicon wafer demand outlook predicts about 6 percent growth in 2003, nearly the same as the previous forecast. However,
More informationDigital Health Startups A FirstWord ExpertViews Dossier Report
AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in
More information3Q03 Silicon Wafer Update: Demand Continues Recovery
Gartner Dataquest Alert 3Q03 Silicon Wafer Update: Demand Continues Recovery The latest silicon forecast indicates that silicon wafer demand will grow 10 percent in 2003 over the previous year. This is
More informationUpdate: SOI Wafer Market Continues Its Growth
Gartner Dataquest Alert Update: SOI Wafer Market Continues Its Growth The results of Gartner Dataquest's latest survey of the silicon on insulator (SOI) wafer market indicate demand grew 16 percent in
More information4Q02 Update: Semiconductor Capacity Still on Hold
Research Brief 4Q02 Update: Semiconductor Capacity Still on Hold Abstract: Semiconductor capacity expansions have gone into a hold mode as soft semiconductor demand drops utilization rates lower. Further
More informationDIGITAL OUTLOOK LIFE SCIENCES INDUSTRY
www.infosys.com INTRODUCTION The life sciences business is facing several challenges as it enters the digital age. Worldwide, sales are slowing down from the heady days of 2014-15 when new drugs for hepatitis
More informationEuropean Enterprises Should Delay a Deployment
Strategic Planning, S. Real Research Note 3 April 2003 European Enterprises Should Delay 802.11a Deployment Inconsistent regulations and an immature standard mean enterprises should not deploy 802.11a
More informationUSTGlobal. How Integrated Data and Technology Affect the Healthcare Ecosystem. UST Global Healthcare Contributed Article
USTGlobal How Integrated Data and Technology Affect the Healthcare Ecosystem UST Global Healthcare Contributed Article UST Global Inc, April 2018 Table of Contents Pharmaceuticals and life sciences Wellness
More informationMichael R. McAlevey, Chief Corporate and Securities Counsel, General Electric Co.
Michael R. McAlevey, Chief Corporate and Securities Counsel, General Electric Co. Michael R. McAlevey, Chief Corporate and Securities Counsel, General Electric Co. Risk taking: the key to securities law
More informationFOREST PRODUCTS: THE SHIFT TO DIGITAL ACCELERATES
FOREST PRODUCTS: THE SHIFT TO DIGITAL ACCELERATES INTRODUCTION While the digital revolution has transformed many industries, its impact on forest products companies has been relatively limited, as the
More informationWhy Artificial Intelligence will Revolutionize Healthcare including the Behavioral Health Workforce.
Why Artificial Intelligence will Revolutionize Healthcare including the Behavioral Health Workforce. NDBH Conference New Orleans, LA October 28, 2018 A D I S T I N C T I V E L Y D I V E R S I F I E D E
More informationPHARMACEUTICALS: WHEN AI ADOPTION HAS GATHERED MOST MOMENTUM.
PHARMACEUTICALS: WHEN AI ADOPTION HAS GATHERED MOST MOMENTUM www.infosys.com/aimaturity It is critical to make sure that society can take full advantage of the capabilities of AI systems while minimizing
More informationAdvancing Health and Prosperity. A Brief to the Advisory Panel on Healthcare Innovation
Advancing Health and Prosperity A Brief to the Advisory Panel on Healthcare Innovation November 2014 About ITAC ITAC is the voice of the Canadian information and communications technologies (ICT) industry
More informationComprehensive Research Services
Comprehensive Research Services Scripps Health: At the Forefront of Clinical Research Scripps Health is a recognized leader in clinical research and has long been at the forefront of numerous medical breakthroughs.
More informationCHINA MED DEVICE. China Medtech Will Continue Its Double Digit Growth in Years to Come
China Medtech Will Continue Its Double Digit Growth in Years to Come The high level characteristics of medtech in China is focused here. Each of the 6 specific sectors according to SWS recommendation will
More informationIndicators Point to Sustainable Semiconductor Market Recovery
Gartner Dataquest Alert Indicators Point to Sustainable Semiconductor Market Recovery Positive leading indicators out of Asia/Pacific and Japan, as well as improved guidance from selected U.S. and European
More informationInnovation and the Changing Practice of Medicine
Innovation and the Changing Practice of Medicine Japan Medical Innovation Symposium David Epstein, Division Head Novartis Pharmaceuticals Tokyo, August 18, 2015 Agenda The Case for Innovation How Novartis
More informationHow machines learn in healthcare
ADVANCES IN DATA SCIENCE How machines learn in healthcare Machine learning is transforming every facet of healthcare, as computer systems are being taught how to use Big Data to derive insights and support
More informationVisual & Virtual Configure-Price-Quote (CPQ) Report. June 2017, Version Novus CPQ Consulting, Inc. All Rights Reserved
Visual & Virtual Configure-Price-Quote (CPQ) Report June 2017, Version 2 2017 Novus CPQ Consulting, Inc. All Rights Reserved Visual & Virtual CPQ Report As of April 2017 About this Report The use of Configure-Price-Quote
More informationACCENTURE INDONESIA HELPS REALIZE YOUR
ACCENTURE INDONESIA HELPS REALIZE YOUR POTEN TIAL ACCENTURE IN INDONESIA Accenture is the largest consulting services company in Indonesia Close to 50 years of experience in Indonesia, and have consistently
More informationTranslational scientist competency profile
C-COMEND Competency profile for Translational Scientists C-COMEND is a two-year European training project supported by the Erasmus plus programme, which started on November 1st 2015. The overall objective
More information(Fig.) JPMA Industry Vision 2025
2. JPMA Industry Vision 2025 Against the background of the changing environment surrounding the pharmaceutical industry and the future predictions *1, we prepared JPMA Industry Vision 2025 Bringing Innovation
More informationGlobal Alzheimer s Association Interactive Network. Imagine GAAIN
Global Alzheimer s Association Interactive Network Imagine the possibilities if any scientist anywhere in the world could easily explore vast interlinked repositories of data on thousands of subjects with
More informationData-Driven Evaluation: The Key to Developing Successful Pharma Partnerships
R&D Solutions for PHARMA & LIFE SCIENCES DRUG DISCOVERY & DEVELOPMENT Data-Driven Evaluation: The Key to Developing Successful Pharma Partnerships Summary For pharmaceutical companies to succeed, it is
More informationAuthors Heidi Gautschi Alexandre Raynaud Damien Vossion Michael Wade. Digital Patient Engagement. Insights for the Pharmaceutical Industry
Authors Heidi Gautschi Alexandre Raynaud Damien Vossion Michael Wade Digital Patient Engagement Insights for the Pharmaceutical Industry March 2018 2 DIGITAL PATIENT ENGAGEMENT: INSIGHTS FOR THE PHARMACEUTICAL
More informationARE LAW FIRMS INNOVATING?
ARE LAW FIRMS INNOVATING? We live in an age that demands innovation. Like it or not, prepared for it or not, the legal market is changing around us. At Thompson Hine, we have embraced that change. Over
More informationFDA Centers of Excellence in Regulatory and Information Sciences
FDA Centers of Excellence in Regulatory and Information Sciences February 26, 2010 Dale Nordenberg, MD novasano HEALTH AND SCIEN Discussion Topics Drivers for evolution in regulatory science Trends in
More information'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint
'INNOVATIVE SOLUTIONS FOR RESEARCH IN HEALTHCARE' Developing a novel approach to deliver better precision medicine in Europe The EMA standpoint STOA workshop - European Parliament, 10 January 2019 Presented
More informationPatenting Strategies. The First Steps. Patenting Strategies / Bernhard Nussbaumer, 12/17/2009 1
Patenting Strategies The First Steps Patenting Strategies / Bernhard Nussbaumer, 12/17/2009 1 Contents 1. The pro-patent era 2. Main drivers 3. The value of patents 4. Patent management 5. The strategic
More informationCross-sector convergence in health. An interview with Jacques Mulder
Cross-sector convergence in health An interview with Jacques Mulder Non-traditional entrants are disrupting health. We are already past the point of no return, says EY s Jacques Mulder. Cross-sector convergence
More informationBoundaryless Hospital - Rethink and Redefine Health Care Management. New Chains of Value Creation
Boundaryless Hospital - Rethink and Redefine Health Care Management New Chains of Value Creation Sören T. Eichhorst, MD PhD Partner and Head of McKinsey Hospital Institute Cologne, Germany PROPRIETARY
More informationSpeed Innovation Happiness. Corporate Overview
Corporate Overview Contents Bilcare Overview Businesses Business Strategy Financial Overview 2 Bilcare Overview 3 Bilcare Overview Our Objective Vision Delivering Innovation Transforming Lives Values Speed
More informationAccenture Technology Vision 2015 Delivering Public Service for the Future Five digital trends: A public service outlook
Accenture Technology Vision 2015 Delivering Public Service for the Future Five digital trends: A public service outlook INFOGRAPHIC Digital government is about using innovative technologies to improve
More informationPromoting Patient and Researcher Engagement with Distributed Data Research Networks through Hurdle Free Tools
Promoting Patient and Researcher Engagement with Distributed Data Research Networks through Hurdle Free Tools pscanner All Hands Symposium 2016 Kari A. Stephens, PhD Psychiatry & Behavioral Sciences Biomedical
More informationUSTGlobal. Internet of Medical Things (IoMT) Connecting Healthcare for a Better Tomorrow
USTGlobal Internet of Medical Things (IoMT) Connecting Healthcare for a Better Tomorrow UST Global Inc, August 2017 Table of Contents Introduction 3 What is IoMT or Internet of Medical Things? 3 IoMT New
More informationMission: Materials innovation
Exploring emerging scientific fields: Big data-driven materials science Developments in methods to extract knowledge from data provide unprecedented opportunities for novel materials discovery and design.
More informationThe robots are coming, but the humans aren't leaving
The robots are coming, but the humans aren't leaving Fernando Aguirre de Oliveira Júnior Partner Services, Outsourcing & Automation Advisory May, 2017 Call it what you want, digital labor is no longer
More informationDigital Medical Device Innovation: A Prescription for Business and IT Success
10 September 2018 Digital Medical Device Innovation: A Prescription for Business and IT Success A Digital Transformation is reshaping healthcare. New technology, mobility, and advancements in computing
More informationKeeping up with the times Tensions between workflow, status quo, and technology
Keeping up with the times Tensions between workflow, status quo, and technology OMG Healthcare and Business Process Modeling Workshop 20 March, 2017 W. Ed Hammond. Ph.D., FACMI, FAIMBE, FIMIA, FHL7 Director,
More informationThriving in the Digital Economy How small and midsize enterprises are adapting to digital transformation
Thriving in the Digital Economy How small and midsize enterprises are adapting to digital transformation February 2016 Thriving in the Digital Economy: Outline Outline» Introduction, page 3» Key Findings,
More informationInsights into Mining. Incremental innovation. Is it the right approach for mining?
Insights into Mining Issue #5 kpmg.ca/mining Welcome to Insights into Mining, a periodic e-newsletter focused on current topics relevant to the Mining Industry. KPMG s mining practice is committed to the
More informationCorporate Mind 2015 Corporate Responsibility Report
Corporate Mind 2015 Corporate Responsibility Report Artwork: Artist s rendering of the components of a cell. Corporate Mind Promega s corporate responsibility program not only helps our life sciences industry
More informationApril By Type of Approach- Transfemoral and Transapical. By Region- North America, Europe, APAC and RoW
Global Transcatheter Aortic Valve Replacement (TAVR) Market: Analysis By Type of Approach (Transfemoral and Transapical), By Region, By Country: Opportunities and Forecast (2017-2022) By Type of Approach-
More informationFall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE
Fall 2015 State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Industry Overview The expansion of Florida s biotech industry remains resilient with an overall growth rate of 92% in the number
More informationWireless Interference in Healthcare Is Real, but Manageable
Technology, K. Kleinberg Research Note 19 March 2003 Wireless Interference in Healthcare Is Real, but Manageable Interference between wireless and electronic devices and medical equipment is a growing
More informationITI Comment Submission to USTR Negotiating Objectives for a U.S.-Japan Trade Agreement
ITI Comment Submission to USTR-2018-0034 Negotiating Objectives for a U.S.-Japan Trade Agreement DECEMBER 3, 2018 Introduction The Information Technology Industry Council (ITI) welcomes the opportunity
More informationResearch Brief. Clinicians and life sciences companies working together: What types of relationships do clinicians find most appealing?
Research Brief Clinicians and life sciences companies working together: What types of relationships do Truven Health Analytics was acquired by IBM in 2016 to help form a new business, Watson Health. Watson
More informationThe Health Information Future: Evolution and/or Intelligent Design?
The Health Information Future: Evolution and/or Intelligent Design? North American Association of Central Cancer Registries Conference Regina, Saskatchewan June 14, 2006 Steven Lewis Access Consulting
More informationResearch and Development Spending
Patented Medicine Prices Review Board Le Conseil d examen du prix des médicaments brevetés PMPRB Study Series S-217 December 22 A Comparison of Pharmaceutical Research and Development Spending in Canada
More informationTransforming How We Manage Health Technologies in Support of Better Health, Better Patient Experience, and Better Value
CADTH 2018 2021 STRATEGIC PLAN Transforming How We Manage Health Technologies in Support of Better Health, Better Patient Experience, and Better Value Health care costs an estimated $242 billion annually
More informationACCELERATING TECHNOLOGY VISION FOR AEROSPACE AND DEFENSE 2017
ACCELERATING TECHNOLOGY VISION FOR AEROSPACE AND DEFENSE 2017 TECHNOLOGY VISION FOR AEROSPACE AND DEFENSE 2017: THROUGH DIGITAL TURBULENCE A powerful combination of market trends, technology developments
More informationPan-Canadian Trust Framework Overview
Pan-Canadian Trust Framework Overview A collaborative approach to developing a Pan- Canadian Trust Framework Authors: DIACC Trust Framework Expert Committee August 2016 Abstract: The purpose of this document
More informationHealth Informaticians Drive Innovation from Bench to Bedside
VIEW FROM THE TOP Health Informaticians Drive Innovation from Bench to Bedside Please tell us about the professionals supported by AMIA: health informatics experts. The professionals in health informatics
More informationHow Machine Learning and AI Are Disrupting the Current Healthcare System. Session #30, March 6, 2018 Cris Ross, CIO Mayo Clinic, Jim Golden, PwC
How Machine Learning and AI Are Disrupting the Current Healthcare System Session #30, March 6, 2018 Cris Ross, CIO Mayo Clinic, Jim Golden, PwC 1 Conflicts of Interest: Christopher Ross, MBA Has no real
More informationA POLICY in REGARDS to INTELLECTUAL PROPERTY. OCTOBER UNIVERSITY for MODERN SCIENCES and ARTS (MSA)
A POLICY in REGARDS to INTELLECTUAL PROPERTY OCTOBER UNIVERSITY for MODERN SCIENCES and ARTS (MSA) OBJECTIVE: The objective of October University for Modern Sciences and Arts (MSA) Intellectual Property
More informationA FORWARD- LOOKING VIEW on how analytics will solve some pressing business, consumer and social insight problems.
A FORWARD- LOOKING VIEW on how analytics will solve some pressing business, consumer and social insight problems. Prabir Sen, Chief Management Scientist, Accenture Adjunct Professor SMU psen@smu.edu.sg
More informationThe Nature of Science
chapter 1 The Nature of Science section 4 Science and Technology What You ll Learn types of technology value of technology consumer effect on technology Before You Read You use different kinds of technology
More informationA Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei
A Brief Introduction to the Regulatory Environment of Medical Device Supervision CFDA Department of Legal Affairs Liu Pei Development Trend of Medical Device Industry Development Opportunities of Medical
More informationWritten Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum
Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum List of recommendations: Recommendation 1: That the government creates a Life Sciences
More informationIntroduction. digitalsupercluster.ca
Introduction digitalsupercluster.ca Government of Canada s Innovation Supercluster Initiative Federal government investing $950MM into superclusters to drive growth, prosperity, jobs and global leadership.
More informationSMA Europe Code of Practice on Relationships with the Pharmaceutical Industry
Introduction SMA Europe Code of Practice on Relationships with the Pharmaceutical Industry SMA Europe is an umbrella body of national Spinal Muscular Atrophy patient representative and research organisations
More informationPRISME Technical Forum Introduction Accelerating Disruption
PRISME Technical Forum Introduction Accelerating Disruption Presenters: Matthew Rich and Jim Golden Agenda Following the Money: Venture Capital s Influence on Pharma Tech Applications and Possibilities
More informationNEWS RELEASE. Life sciences companies tout their expertise in India
For Immediate Release 2014MIT0016-000196 Feb. 19, 2014 NEWS RELEASE International Trade and Responsible for the Asia Pacific Strategy and Multiculturalism Life sciences companies tout their expertise in
More informationWHO WE ARE MISSION STATEMENT
WHO WE ARE Parker Life Sciences offers reliable fluidic and motion control products, MetaModules, and systems to customers in life sciences and in analytical instrumentation markets. As part of Parker
More informationHorizon Societal Challenge 1: Health, demographic change and wellbeing. Jeremy Bray DG Research & Innovation European Commission
Horizon 2020 Societal Challenge 1: Health, demographic change and wellbeing Jeremy Bray DG Research & Innovation European Commission National NHS day Leeds, UK, 29 January 2014 What is Horizon 2020? The
More informationEMA experience with the review of digital technology proposals in medicine development programmes
EMA experience with the review of digital technology proposals in medicine development programmes 3rd Industry Stakeholder Platform on R&D support, 18 May 2018 Francesca Cerreta, Scientific Advice An agency
More informationoverblikk Framtidige teknologier et raskt Erik Lehne Managing Partner, Gartner Consulting
Framtidige teknologier et raskt overblikk Erik Lehne Managing Partner, Gartner Consulting erik.lehne@gartner.com Gartner is a registered trademark of Gartner, Inc. or its affiliates. This publication may
More informationDriving Innovation. Connect and Catalyse. Medicines and Healthcare the Global perspective (+10 years) Zahid Latif
Connect and Catalyse Medicines and Healthcare the Global perspective (+10 years) Zahid Latif % GDP spent on health OECD countries spent nearly $3.5trn in 2005 ($4.6 trillion in 2008) on healthcare services
More informationPower Management Semiconductors: A Preliminary Look
Market Analysis Power Management Semiconductors: A Preliminary Look Abstract: As a key enabler of electronics, power management semiconductors remain fragmented. Benefit from a look into the preliminary
More informationSupporting Innovation through Regulation and Science
Supporting Innovation through Regulation and Science Larry O Dwyer, Scientific Affairs Manager PEARRL Regulatory Science Symposium 21 st June 2017, School of Pharmacy, UCC Overview of Presentation Drivers
More informationKT for TT Ensuring Technologybased R&D matters to Stakeholders. Center on Knowledge Translation for Technology Transfer University at Buffalo
KT for TT Ensuring Technologybased R&D matters to Stakeholders Center on Knowledge Translation for Technology Transfer University at Buffalo Session Objectives 1. Define KT and describe how Models, Methods
More informationChallenges and Opportunities
Challenges and Opportunities in building a Sustainable Global IPR Ecosystem for Promotion of Innovation in ICTE Sector Dr. Santosh Mohanty Tata Consultancy Services Limited India-Europe Conference Friday,
More information2012 North American Laboratory Researchers Choice: Future Market Leader of Digital PCR Technology Award
2011 South African Data Centre Green Excellence Award in Technology Innovation Cybernest 2012 2012 North American Laboratory Researchers Choice: Future Market Leader of Digital PCR Technology Award 2011
More informationGLOBAL ICT REGULATORY OUTLOOK EXECUTIVE SUMMARY
GLOBAL ICT REGULATORY OUTLOOK 2017 EXECUTIVE SUMMARY EXECUTIVE SUMMARY Over past decades the world has witnessed a digital revolution that is ushering in huge change. The rate of that change continues
More informationQuantitative Reasoning: It s Not Just for Scientists & Economists Anymore
Quantitative Reasoning: It s Not Just for Scientists & Economists Anymore Corri Taylor Quantitative Reasoning Program Wellesley College ctaylor1@wellesley.edu In today s world awash in numbers, strong
More informationexecutives are often viewed to better understand the merits of scientific over commercial solutions.
Key Findings The number of new technology transfer licensing agreements earned for every $1 billion of research expenditure has fallen from 115 to 109 between 2004 and. However, the rate of return for
More informationCountry Paper : Macao SAR, China
Macao China Fifth Management Seminar for the Heads of National Statistical Offices in Asia and the Pacific 18 20 September 2006 Daejeon, Republic of Korea Country Paper : Macao SAR, China Government of
More informationClinical Open Innovation
Clinical Open Innovation Reinventing Invention through an Open Clinical Intelligence Network January 2012 A Call to Action by Tom Krohn and Barry Crist, Lilly Clinical Open Innovation In November of 2010,
More informationCOMPREHENSIVE COMPETITIVE INTELLIGENCE MONITORING IN REAL TIME
CASE STUDY COMPREHENSIVE COMPETITIVE INTELLIGENCE MONITORING IN REAL TIME Page 1 of 7 INTRODUCTION To remain competitive, Pharmaceutical companies must keep up to date with scientific research relevant
More informationPrivacy and the EU GDPR US and UK Privacy Professionals
Privacy and the EU GDPR US and UK Privacy Professionals Independent research conducted by Dimensional Research on behalf of TrustArc US 888.878.7830 EU +44 (0)203.078.6495 www.trustarc.com 2017 TrustArc
More informationKen Buetow, Ph.D. Director, Computation Science and Informatics, Complex Adaptive ASU Professor, School of Life Science
COMPLEX ADAPTIVE SYSTEMS Ken Buetow, Ph.D Director, Computation Science and Informatics, Complex Adaptive Systems @ ASU Professor, School of Life Science Kenneth.Buetow@ASU.edu 1 4 th Paradigm Science
More informationA Proposed Probabilistic Model for Risk Forecasting in Small Health Informatics Projects
2011 International Conference on Modeling, Simulation and Control IPCSIT vol.10 (2011) (2011) IACSIT Press, Singapore A Proposed Probabilistic Model for Risk Forecasting in Small Health Informatics Projects
More informationSecurity and Risk Assessment in GDPR: from policy to implementation
Global Data Privacy Security and Risk Assessment in GDPR: from policy to implementation Enisa Workshop Roma - February 8, 2018 Nicola Orlandi Head of Data Privacy Pharma Nicola Orlandi Nicola Orlandi is
More informationBayer Inc. Science for a Better Life. Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division
Bayer Inc. Science for a Better Life Talking with Phil Blake, President, Bayer Inc., HealthCare Representative and Head, Pharmaceuticals Division Please review your career path to date, leading to your
More informationCollaborating with the Office of Technology Transfer
Collaborating with the Office of Technology Transfer Todd Sherer, Ph.D. Associate Vice President for Research and Executive Director Office of Technology Transfer Emory Owns Our IP As a condition of employment,
More informationThe Evolving Eco-system of the Medical Device Industry. An analysis prepared by MassDevice.com
The Evolving Eco-system of the Medical Device Industry An analysis prepared by MassDevice.com Massachusetts Medical Devices Journal LLC, 2008 Who we are MassDevice.com Online business journal covering
More information2016 Executive Summary Canada
5 th Edition 2016 Executive Summary Canada January 2016 Overview Now in its fifth edition and spanning across 23 countries, the GE Global Innovation Barometer is an international opinion survey of senior
More informationTrends Report R I M S
Trends Report R I M S 2 0 1 8 Changing technology Changing workplaces Changing risk Progress is a good thing. But, with evolution and change comes risk. Fast-moving technology and super-charged innovation
More informationWhat is Big Data? Jaakko Hollmén. Aalto University School of Science Helsinki Institute for Information Technology (HIIT) Espoo, Finland
What is Big Data? Jaakko Hollmén Aalto University School of Science Helsinki Institute for Information Technology (HIIT) Espoo, Finland 6.2.2014 Speaker profile Jaakko Hollmén, senior researcher, D.Sc.(Tech.)
More informationA Focus on Health Data Infrastructure, Capacity and Application of Outcomes Data
External Review of Pan-Canadian Health Organizations Thank you for the opportunity to provide input for your ongoing review of the Pan- Canadian Health Organizations (PCHOs). This submission is made on
More informationDigital Identity Innovation Canada s Opportunity to Lead the World. Digital ID and Authentication Council of Canada Pre-Budget Submission
Digital Identity Innovation Canada s Opportunity to Lead the World Digital ID and Authentication Council of Canada Pre-Budget Submission August 4, 2017 Canadian governments, banks, telcos, healthcare providers
More informationImplementation of Systems Medicine across Europe
THE CASyM ROADMAP Implementation of Systems Medicine across Europe A short roadmap guide 0 The road toward Systems Medicine A new paradigm for medical research and practice There has been a data generation
More informationMedtech Slowdown. Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year
www.pwc.com Medtech Slowdown Life sciences venture capital funding lagged behind other industries, declining 10% in 4Q13 and 1% in 2013 over last year February 2014 2 PwC US venture capital funding for
More informationDigital Reality TM changes everything
F E B R U A R Y 2 0 1 8 Digital Reality TM changes everything Step into the future What are we talking about? Virtual Reality VR is an entirely digital world that completely immerses the user in an environment
More informationGuidelines to Promote National Integrated Circuit Industry Development : Unofficial Translation
Guidelines to Promote National Integrated Circuit Industry Development : Unofficial Translation Ministry of Industry and Information Technology National Development and Reform Commission Ministry of Finance
More informationFinancing Growth Ventures to Minimize Equity Dilution
Financing Growth Ventures to Minimize Equity Dilution An entrepreneurial team s mission is to develop and grow its venture and to optimize the management team s equity ownership stake. Significant growth
More informationCEOCFO Magazine. Pat Patterson, CPT President and Founder. Agilis Consulting Group, LLC
CEOCFO Magazine ceocfointerviews.com All rights reserved! Issue: July 10, 2017 Human Factors Firm helping Medical Device and Pharmaceutical Companies Ensure Usability, Safety, Instructions and Training
More informationOverview of Intellectual Property Policy and Law of China in 2017
CPI s Asia Column Presents: Overview of Intellectual Property Policy and Law of China in 2017 By LIU Chuntian 1 & WANG Jiajia 2 (Renmin University of China) October 2018 As China s economic development
More information